Hello, I’m Dr Jonathan Abbas. I’m the director of the acute leukemia and blood cancer program with Tennessee Oncology in Nashville, Tennessee. I specialize in hematologic malignancies, specifically acute leukemia, and my center treats over a hundred patients a year with aggressive chemotherapy for AML many of whom have sAML, including t-AML and AML-MRC.
Prior to initiating each cycle of VYXEOS, calculate the prior cumulative anthracycline exposure for the patient. Administer prophylactic anti-emetics before treatment with VYXEOS.
Prior to initiating induction, assess cardiac function and obtain liver and renal function studies.
After induction therapy with VYXEOS, bone marrow assessment should be conducted to determine if the patient has achieved a CR.
For patients who do not achieve remission with the first induction cycle, a second induction cycle may be administered 2 to 5 weeks after the first if there was no unacceptable toxicity with VYXEOS.
Administer the first consolidation cycle 5 to 8 weeks after the start of the last induction.
Administer the second consolidation cycle 5 to 8 weeks after the start of the first consolidation cycle in patients who do not show disease progression or unacceptable toxicity to VYXEOS.
VYXEOS is indicated for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t‑AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.
IMPORTANT SAFETY INFORMATION